Summit Securities Group’s Cardiff Oncology CRDF Stock Holding History

Summit Securities Group’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	–	Sell	-1	Closed	–	–	534
2013 Q3	$0	Buy	+1	New	+$569	﹤0.01%	446

Other funds holding CRDF

Bridger Management New York $150M AUM 17.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RPAM

Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AGM

Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Summit Securities Group's CRDF Position: Q4 2013 in Review

Summit Securities Group sold out of Cardiff Oncology (CRDF) in Q4 2013, closing a stake of 1 share.

Summit Securities Group first reported a position in CRDF in Q3 2013 and held it in 1 quarter. The position peaked at $0 in Q3 2013. 26 funds tracked by Wall St. Rank hold CRDF as of Q4 2013.

Summit Securities Group reported no remaining Cardiff Oncology position as of Q4 2013 after selling out during the quarter.
Summit Securities Group sold 1 Cardiff Oncology share in Q4 2013.
Summit Securities Group first reported a position in Cardiff Oncology in Q3 2013 and held it in 1 quarter.
Summit Securities Group's Cardiff Oncology position peaked at $0 in Q3 2013.
26 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2013.

Based on Summit Securities Group's 13F filing for Q4 2013, filed 13 Feb 2014.